1114591-99-9Relevant academic research and scientific papers
Compounds and methods of use
-
Page/Page column 454; 455, (2021/08/04)
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
Discovery of a novel series of potent S1P1 agonists
Crosignani, Stefano,Bombrun, Agnes,Covini, David,Maio, Maurizio,Marin, Delphine,Quattropani, Anna,Swinnen, Dominique,Simpson, Don,Sauer, Wolfgang,Fran?on, Bernard,Martin, Thierry,Cambet, Yves,Nichols, Anthony,Martinou, Isabelle,Burgat-Charvillon, Fabienne,Rivron, Delphine,Donini, Cristina,Schott, Olivier,Eligert, Valerie,Novo-Perez, Laurence,Vitte, Pierre-Alain,Arrighi, Jean-Fran?ois
supporting information; experimental part, p. 1516 - 1519 (2010/06/21)
The discovery of a novel series of S1P1 agonists is described. Starting from a micromolar HTS positive, iterative optimization gave rise to several single-digit nanomolar S1P1 agonists. The compounds were able to induce internalization of the S1P1 receptor, and a selected compound was shown to be able to induce lymphopenia in mice after oral dosing.
6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS
-
Page/Page column 98-99, (2009/04/25)
The invention relates to compounds of formula (I): wherein X, W, Q, R, R1 and R2 have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
